Stereotaxis Showcases AI and Automation Tech at HRX 2026
Event summary
- Stereotaxis will feature its digital and robotic technologies, including Synchrony and SynX, at the Heart Rhythm Society’s HRX conference from September 18-20, 2026.
- CEO David Fischel will join a main-stage panel on September 19th to discuss autonomous EP systems.
- Synchrony received FDA clearance earlier this year and is already in use at multiple clinical sites in the US and Europe.
- Stereotaxis is developing enhanced automation capabilities for catheter and interventional device navigation.
The big picture
Stereotaxis is positioning itself at the forefront of the digital transformation in cardiovascular medicine, leveraging AI and automation to enhance procedural workflows. The company's focus on integrating these technologies into its robotic systems aligns with broader industry trends toward minimally invasive interventions and smart operating rooms. With over 150,000 patients treated using its technology, Stereotaxis is well-placed to capitalize on the growing demand for advanced cardiovascular solutions.
What we're watching
- Adoption Pace
- How quickly Synchrony and SynX will be adopted by clinical sites beyond early adopters.
- Regulatory Hurdles
- Whether Stereotaxis can sustain the pace of regulatory approvals for its automation capabilities.
- Market Differentiation
- The extent to which Stereotaxis can differentiate itself in the competitive landscape of surgical robotics.
Related topics